Results 41 to 50 of about 11,119 (184)
Addiction, EarlyView.Abstract Aim Our primary aim was to conduct a network meta‐analysis (NMA) for the effectiveness, safety and acceptability of all psychosocial interventions and all pharmacotherapies for cannabis use disorder (CUD). Methods We conducted a NMA of studies identified from two completed systematic reviews examining the effectiveness, safety and ...
Monika Halicka +6 more
wiley +1 more source
Varenicline increases random flap survival in rats submitted to nicotine
, 2018 Smoking is a leading cause of flap failure. Varenicline-assisted smoking cessation has shown beneficial effects on vascular endothelial function. The aim of this study was to determine whether varenicline conveys beneficial effects for skin flap survival.
Bitik, Ozan +6 more
core +1 more source
Meta-Analysis of the Role of Varenicline in Smoking Cessation [PDF]
, 2022 Background: Smoking is the leading cause of premature death in both developed and developing countries. Smoking cessation efforts can be classified into pharmacological and therapeutic strategies.
Prasetya, Hanung +2 more
core +1 more source
Varenicline: a review of the literature and place in therapy [PDF]
, 2007 Evidence regarding the health consequences of smoking is undeniable, yet 21% of the American population continues to smoke. In addition to behavioral modifications, first-line treatment options include nicotine replacement therapies and bupropion SR ...
Whitley,Heather P., Moorman,Krystal L.
core +3 more sources
Beyond abstinence: Redefining success in cannabis use disorder treatment
Addiction, EarlyView.Abstract Background Over two decades of pharmacotherapy research has yet to yield a consistently effective medication for cannabis use disorder (CUD), in part because clinical trials have frequently prioritized abstinence as a primary or key endpoint.
Tobias B. Atkin +3 more
wiley +1 more source
Addiction, EarlyView.Abstract Background and aims Globally, around 11% of adolescents aged 13–15 years use tobacco products, and over one‐third of users are estimated to be tobacco dependent. Interventions to support adolescents to quit smoking are recommended to mitigate adverse health effects.
Courtney Barnes +12 more
wiley +1 more source
Addiction, EarlyView.Abstract Background and aims Australia experienced a prolonged varenicline shortage beginning June 2021, disrupting access to a key smoking cessation therapy. Section 19A (S19A) of the Therapeutic Goods Act permitted temporary importation of overseas‐approved products to mitigate this impact.
Chloe Weigall +6 more
wiley +1 more source
Addiction, EarlyView.Abstract Background and aims Nicotine Vaping Products are widely used, effective tools for smoking cessation, despite not being approved medicines. Public beliefs that vaping is more harmful than smoking have increased contrary to accumulating evidence. This study explored trends in beliefs about the efficacy of vaping for smoking cessation.
Bibha Dhungel +5 more
wiley +1 more source
Cancer pain: current practice and emerging targets
British Journal of Pharmacology, EarlyView.Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye +5 more
wiley +1 more source
, 2018 Introduction Numerous studies have evaluated the efficacy and safety of varenicline for smoking cessation in smokers in the general population and, to a lesser extent, among the psychiatric population.
Silvia Mondon +7 more
core +1 more source